MedeliX
Start asking

aprepitant

Emend · ATC code A04AD12

Brand names: Emend, Aprepitant Accord, Aprepitant Ratiopharm, Aprepitant Sandoz, Aprepilor, Aprepitant Al, Aprepitant Beta, Aprepitant Heumann, Aprepitant Hexal, Aprepitant Qilu, Aprepitant Stada, Aprepitant Zentiva, Fosaprant, Fosemazon, Fosemitant

Key facts
Active substance
aprepitant
ATC code
A04AD12
Authorisation
centrally authorised across the EU (EMA)
Dosage forms
EMEND 125 mg hard capsules / EMEND 80 mg hard capsules · EMEND 125 mg powder for oral suspension
Marketing authorisation holder
Merck Sharp & Dohme B.V.
Information as of
2026-10-27

Key facts

Aprepitant is a neurokinin-1 receptor antagonist used to prevent nausea and vomiting with highly and moderately emetogenic cancer chemotherapy, as part of combination therapy.

What it is used for

  • Hard capsules: prevention of chemotherapy-induced nausea and vomiting in adults and adolescents from the age of 12
  • Powder for oral suspension: children from 6 months to less than 12 years
  • Always given as part of combination therapy

Dosing

  • Adults (capsules): 125 mg one hour before chemotherapy on Day 1, 80 mg in the morning on Days 2 and 3, with a corticosteroid and a 5-HT3 antagonist
  • Adolescents aged 12 through 17 (capsules): 125 mg on Day 1, 80 mg on Days 2 and 3
  • Oral suspension (6 months to less than 12 years, at least 6 kg): Day 1 3 mg/kg (max 125 mg), Days 2 and 3 2 mg/kg (max 80 mg)
  • In children and adolescents, a co-administered corticosteroid is given at 50 % of the usual dose
  • No dose adjustment in the elderly or renal impairment; caution in moderate to severe hepatic impairment

Contraindications

  • Hypersensitivity to the active substance or any excipient
  • Co-administration with pimozide, terfenadine, astemizole or cisapride

Important warnings

  • Caution in moderate to severe hepatic impairment (limited or no data)
  • Caution with oral CYP3A4 substrates with a narrow therapeutic range (e.g. cyclosporine, tacrolimus, fentanyl); particular caution with irinotecan
  • Warfarin: INR monitored closely during treatment and for 14 days after each 3-day course
  • Hormonal contraceptives may be less effective during and for 28 days after administration

Side effects

  • Adults (HEC): hiccups, ALT increased, dyspepsia, constipation, headache, decreased appetite
  • Adults (MEC): fatigue
  • Paediatric patients: hiccups and flushing

Interactions

  • Aprepitant is a substrate, moderate inhibitor and inducer of CYP3A4, and an inducer of CYP2C9
  • After treatment ends: transient mild induction of CYP2C9, CYP3A4 and glucuronidation
  • The adult dexamethasone doses account for the interaction

Pregnancy and breastfeeding

  • Non-hormonal back-up contraception during treatment and for 2 months after the last dose
  • Further information on pregnancy and breast-feeding is in the full text

Summary of the official product information, written with AI (Claude, Anthropic) on 2026-10-28. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.

Full official text →

Common questions – ask Medelix

For patients

Package leaflet, verbatim

Package leaflet for patients →

Authorisation and brand names by country

Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.

EU – centrally authorised (all member states)

  • EmendMerck Sharp & Dohme B.V. · EMEA/H/C/000527

Source: European Medicines Agency (EMA), product information

Austria

  • Aprepitant AccordAccord Healthcare B.V. · 1 register entry
  • Aprepitant RatiopharmTeva B.V · 1 register entry
  • Aprepitant SandozSandoz Gmbh · 1 register entry

Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-28

Germany

  • AprepilorEthypharm · 1 register entry
  • Aprepitant AlAliud Pharma Gmbh · 1 register entry
  • Aprepitant BetaBetapharm Arzneimittel Gmbh · 1 register entry
  • Aprepitant HeumannHeumann Pharma Gmbh & Co. Generica Kg · 1 register entry
  • Aprepitant HexalHexal Ag · 1 register entry
  • Aprepitant QiluQilu Pharma Spain S.L. · 1 register entry
  • Aprepitant RatiopharmRatiopharm Gmbh · 1 register entry
  • Aprepitant StadaStadapharm Gmbh · 1 register entry
  • Aprepitant ZentivaZentiva Pharma Gmbh · 1 register entry

Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-28

Turkey

  • EmendMERCK SHARP DOHME İLAÇLARI LTD. ŞTİ. · 1 register entry
  • FosaprantVEM İLAÇ SAN. VE TİC. A.Ş. · 1 register entry
  • FosemazonPOLİFARMA İLAÇ SAN. VE TİC. A.Ş. · 1 register entry
  • FosemitantAROMA İLAÇ SAN. LTD. ŞTİ. · 1 register entry

Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-10-16

Brand names in 24 more European countries
Belgium
Aprepitant Sandoz, Aprepitant Teva
Croatia
Aprepitant Alpha-Medical, Aprepitant Sandoz, Aprepitant Teva
Cyprus
Atanto, Endrem
Czechia
Aprepitant Accord, Aprepitant Sandoz, Aprepitant Teva
Denmark
Aprepitant "medical Valley", Aprepitant Medical Valley, Aprepitant Sandoz, Aprepitant Stada, Arepitant Stada
Estonia
Aprepitant Sandoz
Finland
Aprepitant Stada
France
Aprepitant Accord, Aprepitant Aprepitant, Aprepitant Arrow, Aprepitant Biogaran, Aprepitant Cristers, Aprepitant Eg, Aprepitant Evolugen, Aprepitant Qilu, Aprepitant Sandoz, Aprepitant Teva, Aprepitant Viatris, Aprepitant Zentiva, Atanto, Lorpitan
Greece
Aprepitant Win Medica, Atanto, Inepitant
Hungary
Aprepitant Pharmacenter, Aprepitant Q Pharma, Aprepitant Sandoz, Aprepitant Win Medica
Iceland
Aprepitant Medical Valley, Aprepitant Stada, Emend, Tiperant
Ireland
Aprepitant Accord
Italy
Aprepitant Accord, Aprepitant Teva, Atanto
Latvia
Aprepitant Sandoz
Liechtenstein
Emend
Lithuania
Aprepitant Sandoz
Netherlands
Aprepitant Accord, Aprepitant Aurobind, Aprepitant Aurobindo, Aprepitant Cf, Aprepitant Sandoz, Aprepitant Teva, Aprepitant Xiromed, Aprepitant Zentiva, Atanto
Norway
Emend
Poland
Aprepitant Accord, Aprepitant Sandoz, Aprepitant Stada, Aprepitant Viatris
Portugal
Aprepitant Generis
Slovakia
Aprepitant
Slovenia
Aprepitant Teva
Spain
Aprepitant Accord, Aprepitant Qilu, Aprepitant Sandoz
Sweden
Aprepitant Medical Valley, Aprepitant Stada

EMA – Article 57 product data (EU/EEA), 2026-10-28

Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.

Another question about this substance?

Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.

Sources

  1. European Medicines Agency. Emend – EPAR, Product Information (OF THE TEXT Detailed information on this medicinal product i). 2026-10-27. https://www.ema.europa.eu/en/documents/product-information/emend-epar-product-information_en.pdf
  2. EMA – Article 57 product data (EU/EEA), 2026-10-28. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
  3. EMA – Article 57 product data (EU/EEA), 2026-10-28. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
  4. TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-10-16. https://www.titck.gov.tr/dinamikmodul/85

Editorial: Medelix editorial team · last updated 2026-10-27 · How these pages are made · Report an error

Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.